相关实验视频
Updated: Jul 22, 2026
09:53
In vivo Imaging of Transgenic Leishmania Parasites in a Live Host
Published on: July 27, 2010
16.0K
关于药物不耐受性和利什曼病疫苗开发的审查
Priya Kumari1, Afrin Mamud2, Anupam Nath Jha2
1Centre of Sustainable Polymers, Indian Institute of Technology, Guwahati, Assam, India.
Current drug targets
|October 12, 2023
概括
由于治疗方法有限和药物耐药性,开发有效的莱什曼病疫苗至关重要. 狗莱什曼病疫苗的成功为人类莱什曼病疫苗的开发提供了希望.
科学领域:
- 医学寄生虫学 医学寄生虫学
- 热带医学 热带医学
- 疫苗学 疫苗学 疫苗学
背景情况:
- 莱什曼病是一种被沙传播的被忽视的热带疾病 (NTD),导致全球严重的残疾和死亡率.
- 内脏莱什曼病 (VL) 是最致命的形式,在东非和南亚流行,治疗选择有限,药物耐药性越来越强.
- 目前用于莱什曼病的治疗方法具有严重的副作用,需要开发更安全,更具成本效益的替代方案.
研究的目的:
- 审查目前的方法和发展针对莱什曼病的疫苗的进展.
- 为了强调由于治疗限制和耐药性,迫切需要新型疫苗.
- 基于对犬类莱什曼病的成功,探索疫苗开发的潜力.
主要方法:
- 关于莱什曼病疫苗研究的科学文献的综述.
- 对候选疫苗的临床前和临床试验数据的分析.
- 检查用于开发皮肤 (CL) 和内脏莱什曼病 (VL) 疫苗的策略.
主要成果:
- 迄今为止,没有人体莱什曼病疫苗成功完成了所有临床试验.
- 几种候选疫苗正处于临床前和临床开发的不同阶段.
- 针对犬类莱什曼病 (CanL) 的成功商用疫苗证明了莱什曼病疫苗开发的可行性.
结论:
- 疫苗代表了一种有希望的低风险,有效的预防利什曼病的策略,可能提供长期的免疫力.
- 持续的研究和开发对于克服人类莱什曼病疫苗制造方面的挑战至关重要.
- 在CanL疫苗接种方面的进展为未来人类莱什曼病疫苗提供了积极的前景.
相关概念视频
01:29Microorganisms in Medicine and Therapeutics
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
01:30Leishmaniasis
Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...